Zimbabwe has rejected a major US health deal worth $367m (272 million pounds) over five years because of Washington's insistence on confidential biological samples.
This rejection came to light following a internal memorandum dated December was leaked, which showed President Emmerson Mnangagwa believed the arrangement was "unbalanced".
A government spokesman later stated that the US was requesting biological samples for research and profit but refused to guarantee the benefits from future medical innovations.
"We must now begin the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for more talks to secure a deal suitable to both sides so the country's critical HIV programme can be sustained.
Wider Implications
This rejection comes after a similar situation in neighbouring Kenya, where a high court halted a related deal with the US following concerns were raised about the safety of citizens' health data.
After resuming office last year, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump stated its spending was "wasteful" and his government was seeking direct bilateral agreements to boost transparency and accountability.
According to statements, 16 African countries have to date agreed to these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation would have delivered significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving HIV treatment via US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to provide its genetic material and health information for a long time, with no equivalent promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"Effectively, our country would supply the basic resources for scientific discovery without any assurance that the resulting innovations would be accessible to our population if a future health crisis arise."
National Interest and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were upending structures previously set up through the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system designed to deal with potential global health emergencies.
"This system is designed to ensure that when a country provides its information, the benefits – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the capability to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as opposition to America," he added.
"We welcome further discussions with our American counterparts on how subsequent collaboration could be arranged in a manner that honours the sovereignty and interests of each country."
Medical Community Response
A leading public health body said it understood the government's concerns, but recommended that negotiations should continue considering a large portion of the nation's HIV programmes were funded by foreign aid.
"If specific concerns arise, including those relating to information security or agreement terms, these can often be resolved through technical clarification and negotiated safeguards," it commented.
This impasse emphasises the ongoing tensions between receiving crucial international aid and safeguarding local interests in an increasingly data-driven world.